Large tumor suppressor 2 is a prognostic biomarker and correlated with immune infiltrates in colorectal cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Ning T, Li J, He Y, et al. Exosomal miR-208b related with oxaliplatin resistance promotes tregs expansion in colorectal cancer. Mol Ther. 2021;29(9):2723–2736.
   PubMed Web of Science ®Google Scholar
• Jo YK, Roh SA, Lee H, et al. Polypyrimidine tract-binding protein 1-mediated down-regulation of ATG10 facilitates metastasis of colorectal cancer cells. Cancer Lett. 2017;385:21–27.
   PubMed Web of Science ®Google Scholar
• Liu C, Hu C, Li J, et al. Identification of epithelial-mesenchymal transition-related lncRNAs that associated with the prognosis and immune microenvironment in colorectal cancer. Front Mol Biosci. 2021;8:633951.
   PubMed Web of Science ®Google Scholar
• Wu D, Zhu Y. Role of kynurenine in promoting the generation of exhausted CD8+ T cells in colorectal cancer. Am J Transl Res. 2021;13(3):1535–1547.
   PubMed Web of Science ®Google Scholar
• Olguín JE, Medina-Andrade I, Rodríguez T, et al. Relevance of regulatory T cells during colorectal cancer development. Cancers (Basel). 2020;12(7):1888.
   PubMed Web of Science ®Google Scholar
• Yi B, Cheng H, Wyczechowska D, et al. Sulindac modulates the response of proficient MMR colorectal cancer to anti-PD-L1 immunotherapy. Mol Cancer Ther. 2021;20(7):1295–1304.
   PubMed Web of Science ®Google Scholar
• Furth N, Aylon Y. The LATS1 and LATS2 tumor suppressors: beyond the Hippo pathway. Cell Death Differ. 2017;24(9):1488–1501.
   PubMed Web of Science ®Google Scholar
• Murakami H, Mizuno T, Taniguchi T, et al. LATS2 is a tumor suppressor gene of malignant mesothelioma. Cancer Res. 2011;71(3):873–883.
   PubMed Web of Science ®Google Scholar
• Zhang C, Cao J, Lv W, et al. CircRNA_100395 carried by exosomes from Adipose-Derived mesenchymal stem cells inhibits the malignant transformation of non-small cell lung carcinoma through the miR-141-3p-LATS2 axis. Front Cell Dev Biol. 2021;9:663147.
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Miyoshi Y, Takahata C, et al. Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers. Clin Cancer Res. 2005;11(4):1380–1385.
   PubMed Web of Science ®Google Scholar
• Guo C, Wang X, Liang L. LATS2-mediated YAP1 phosphorylation is involved in HCC tumorigenesis. Int J Clin Exp Pathol. 2015;8(2):1690–1697.
   PubMed Web of Science ®Google Scholar
• Feng S, Sun H, Zhu W. MiR-92 overexpression suppresses immune cell function in ovarian cancer via LATS2/YAP1/PD-L1 pathway. Clin Transl Oncol. 2021;23(3):450–458.
   PubMed Web of Science ®Google Scholar
• Zhang X, Wang W, Li P, et al. High TREM2 expression correlates with poor prognosis in gastric cancer. Hum Pathol. 2018;72:91–99.
   PubMed Web of Science ®Google Scholar
• Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10(21):7252–7259.
   PubMed Web of Science ®Google Scholar
• Mootha V, Lindgren C, Eriksson K, et al. PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes. Nat Genet. 2003;34(3):267–273.
   PubMed Web of Science ®Google Scholar
• Subramanian A, Tamayo P, Mootha V, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545–15550.
   PubMed Web of Science ®Google Scholar
• Liberzon A, Birger C, Thorvaldsdottir H, et al. The Molecular Signatures Database (MSigDB) hallmark gene set collection. Cell Syst. 2015;1(6):417–425.
   PubMed Web of Science ®Google Scholar
• Li B, Severson E, Pignon J, et al. Comprehensive analyses of tumor immunity: implications for cancer immunotherapy. Genome Biol. 2016;17(1):174.
   PubMed Web of Science ®Google Scholar
• Li T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells. Cancer Res. 2017;77(21):e108–e110.
   PubMed Web of Science ®Google Scholar
• Montojo J, Zuberi K, Rodriguez H, et al. GeneMANIA: fast gene network construction and function prediction for Cytoscape. F1000Res. 2014;3:153.
   PubMedGoogle Scholar
• Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420(6917):860–867.
   PubMed Web of Science ®Google Scholar
• Franciszkiewicz K, Boissonnas A, Boutet M, et al. Role of chemokines and chemokine receptors in shaping the effector phase of the antitumor immune response. Cancer Res. 2012;72(24):6325–6332.
   PubMed Web of Science ®Google Scholar
• Sharma R, Chheda Z, Jala V, et al. Regulation of cytotoxic T-Lymphocyte trafficking to tumors by chemoattractants: implications for immunotherapy. Expert Rev Vaccines. 2015;14(4):537–549.
   PubMed Web of Science ®Google Scholar
• Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev. 2002;13(2):95–109.
   PubMed Web of Science ®Google Scholar
• Ni Y-H, Zhang -X-X, Lu Z-Y, et al. Tumor-infiltrating CD1a+ DCs and CD8+/FoxP3+ ratios served as predictors for clinical outcomes in tongue squamous cell carcinoma patients. Pathol Oncol Res. 2020;26(3):1687–1695.
   PubMed Web of Science ®Google Scholar
• Wang -S-S, Liu W, Ly D, et al. Tumor-infiltrating B cells: their role and application in anti-tumor immunity in lung cancer. Cell Mol Immunol. 2019;16(1):6–18.
   PubMed Web of Science ®Google Scholar
• Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960–1964.
   PubMed Web of Science ®Google Scholar
• Melaiu O, Chierici M, Lucarini V, et al. Cellular and gene signatures of tumor-infiltrating dendritic cells and natural-killer cells predict prognosis of neuroblastoma. Nat Commun. 2020;11(1):5992.
   PubMed Web of Science ®Google Scholar
• Bremnes RM, Busund L-T, Kilvær TL, et al. The role of tumor-infiltrating lymphocytes in development, progression, and prognosis of non-small cell lung cancer. J Thorac Oncol. 2016;11(6):789–800.
   PubMed Web of Science ®Google Scholar
• Ma S, Meng Z, Chen R, et al. The Hippo pathway: biology and pathophysiology. Annu Rev Biochem. 2019;88(1):577–604.
   PubMedGoogle Scholar
• Yang H, Hall SRR, Sun B, et al. NF2 and Canonical Hippo-YAP pathway define distinct tumor subsets characterized by different immune deficiency and treatment implications in human pleural mesothelioma. Cancers (Basel). 2021;13(7):1561.
   PubMed Web of Science ®Google Scholar